Reddymasu Savio C, Soykan Irfan, McCallum Richard W
Department of Medicine, Center for Gastrointestinal Motility, Division of Gastroenterology and Hepatology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA.
Am J Gastroenterol. 2007 Sep;102(9):2036-45. doi: 10.1111/j.1572-0241.2007.01255.x. Epub 2007 May 3.
Domperidone is a dopamine-2 receptor antagonist. It acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine. Unlike metoclopramide, it does not cause any adverse neurological symptoms as it has minimal penetration through the blood-brain barrier. It thus provides an excellent safety profile for long-term administration orally in the recommended doses. Domperidone is widely used in many countries and can now be officially prescribed to patients in the United States by an investigational new drug application for the treatment of gastroparesis and any condition causing chronic nausea and vomiting. In view of this additional clinical exposure of domperidone to a new generation of gastroenterologists and other specialists, the purpose of this timely review is to revisit the pharmacology, clinical application, and safety profile of this beneficial medication.
多潘立酮是一种多巴胺-2受体拮抗剂。它通过作用于化学感受器触发区以及胃和小肠的运动功能,起到止吐和促动力作用。与甲氧氯普胺不同,它极少透过血脑屏障,不会引起任何不良神经症状。因此,按推荐剂量长期口服具有良好的安全性。多潘立酮在许多国家广泛使用,目前在美国,通过研究性新药申请,它可正式用于治疗胃轻瘫以及任何导致慢性恶心和呕吐的病症。鉴于新一代胃肠病学家和其他专科医生对多潘立酮有了更多的临床接触,本次及时的综述旨在重新审视这种有益药物的药理学、临床应用及安全性。